Goldman Sachs Optimistic About Regenxbio’s Gene Therapy Pipeline, Sees Over 160% Upside
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
Class Action Against Abbott’s Glucerna Products Proceeds in Federal Court
WuXi AppTec employees collaborated with China's PLA on altitude sickness drugs, raising national security concerns in the U.S. Congressional committee calls for restricting biotech ties amid ongoing scrutiny.
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1.
Why Is Robotic Surgery-Focused Penny Stock Asensus Surgical Trading Higher On Friday?
KARL STORZ Endoscopy-America has agreed to acquire Asensus Surgical for $0.35 per share, representing a 67% premium. This acquisition will bolster KARL STORZ's robotic surgical market presence.
Over 10,000 Lawsuits In Novo Nordisk’s Ozempic Case Assigned to New Judge
Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest.
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments.
AbbVie’s Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the biosimilar market and prompting calls for regulatory reform to enhance patient access and incentivize development.
FDA Approves Geron’s First Commercial Drug, Competes With Bristol Myers Squibb’s Blood Cancer Drug
FDA approves Geron's Rytelo (imetelstat) for adults with low-to intermediate-1 risk myelodysplastic syndromes and transfusion-dependent anemia Geron's first commercial treatment targets a market potential of $1.2 billion.
Some Breather For E-Cigarette Maker Juul As FDA Reconsiders Marketing Denials Issued Two Years Ago
FDA rescinds marketing denial orders for JUUL Labs Inc., pending further review. Recent case law influences decision. FDA seeks scientific soundness in e-cigarette approval process. JUUL's financial woes continue amid regulatory uncertainty.
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis.